Bank Julius Baer & Co. Ltd Zurich decreased its position in shares of IQVIA Holdings Inc. (NYSE:IQV - Free Report) by 9.0% during the 1st quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 53,099 shares of the medical research company's stock after selling 5,266 shares during the period. Bank Julius Baer & Co. Ltd Zurich's holdings in IQVIA were worth $9,907,000 at the end of the most recent quarter.
Several other hedge funds have also recently bought and sold shares of IQV. Norges Bank acquired a new stake in IQVIA in the 4th quarter valued at about $336,041,000. Invesco Ltd. raised its position in IQVIA by 53.4% in the 4th quarter. Invesco Ltd. now owns 2,590,260 shares of the medical research company's stock valued at $509,012,000 after purchasing an additional 902,226 shares in the last quarter. Canada Pension Plan Investment Board raised its position in IQVIA by 20.0% in the 4th quarter. Canada Pension Plan Investment Board now owns 4,282,024 shares of the medical research company's stock valued at $841,461,000 after purchasing an additional 712,958 shares in the last quarter. D. E. Shaw & Co. Inc. raised its position in IQVIA by 211.2% in the 4th quarter. D. E. Shaw & Co. Inc. now owns 965,302 shares of the medical research company's stock valued at $189,691,000 after purchasing an additional 655,153 shares in the last quarter. Finally, Marshall Wace LLP raised its position in IQVIA by 85.4% in the 4th quarter. Marshall Wace LLP now owns 954,294 shares of the medical research company's stock valued at $187,528,000 after purchasing an additional 439,649 shares in the last quarter. Institutional investors and hedge funds own 89.62% of the company's stock.
Analyst Upgrades and Downgrades
A number of research firms have recently commented on IQV. HSBC downgraded IQVIA from a "buy" rating to a "hold" rating and dropped their price objective for the company from $260.00 to $160.00 in a report on Friday, April 25th. Evercore ISI increased their price objective on IQVIA from $170.00 to $180.00 and gave the company an "outperform" rating in a report on Wednesday, July 9th. Barclays increased their price objective on IQVIA from $165.00 to $185.00 and gave the company an "equal weight" rating in a report on Wednesday. Cowen reiterated a "buy" rating on shares of IQVIA in a report on Wednesday. Finally, Redburn Partners set a $188.00 price target on IQVIA in a research note on Friday, May 23rd. Seven investment analysts have rated the stock with a hold rating, seventeen have given a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $228.62.
Check Out Our Latest Research Report on IQVIA
IQVIA Price Performance
IQV stock traded down $1.41 during midday trading on Friday, hitting $199.41. 1,437,820 shares of the stock were exchanged, compared to its average volume of 2,038,182. The stock's 50-day moving average price is $155.96 and its 200-day moving average price is $170.53. The stock has a market cap of $33.90 billion, a price-to-earnings ratio of 28.86, a PEG ratio of 2.29 and a beta of 1.30. IQVIA Holdings Inc. has a fifty-two week low of $134.65 and a fifty-two week high of $252.88. The company has a debt-to-equity ratio of 2.45, a quick ratio of 0.82 and a current ratio of 0.84.
IQVIA (NYSE:IQV - Get Free Report) last released its quarterly earnings results on Tuesday, July 22nd. The medical research company reported $2.81 earnings per share for the quarter, topping analysts' consensus estimates of $2.77 by $0.04. IQVIA had a return on equity of 30.05% and a net margin of 7.88%. The company had revenue of $4.02 billion during the quarter, compared to analysts' expectations of $3.96 billion. During the same period in the previous year, the firm posted $2.64 earnings per share. The business's revenue for the quarter was up 5.3% compared to the same quarter last year. Research analysts predict that IQVIA Holdings Inc. will post 10.84 earnings per share for the current year.
About IQVIA
(
Free Report)
IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.
Recommended Stories
Before you consider IQVIA, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and IQVIA wasn't on the list.
While IQVIA currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
